# A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)

> **NCT01082887** · PHASE1,PHASE2 · TERMINATED · sponsor: **Nantes University Hospital** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **OTHER:** TIL-Ad-INFg

## Key facts

- **NCT ID:** NCT01082887
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01082887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01082887, "A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT01082887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*